Company Description

Helicore is a clinical stage biopharmaceutical company focused on the discovery and development of a portfolio of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. The company’s novel approach to GIP antagonism — monoclonal antibodies that bind circulating GIP ligand — serves as the backbone of a highly modular platform for anti-obesity medicines that have the potential to offer improved efficacy, dosing and tolerability.